Press Releases

Marietta, Ohio, Feb. 19, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders. “Using isolated cardiac cells, we demonstrated that PKX-001 exerts cardioprotective effects in cells that are exposed to stress induced by nutrient overload or cardiotoxic drugs. Specifically, PKX-001 minimized cardiac cell damage and […]

Marietta, Ohio, February 11, 2020                                                                                                      ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for a new application of its AAGP® molecule.  During recent testing at The University of British Columbia, where photo receptors were transplanted into animal models, it was observed that AAGP® may have had a role […]

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that the Company has taken procession of an additional 200 grams of GMP grade PKX-001 (AAGP®) molecule. We are shipping sufficient molecule to Iotron Industries in British Columbia for sterilization.  The sterilization process is a 1-week turnaround. After sterilization there will be one more […]

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to date have shown no sign of irritation. About ITR Laboratories Based on this ProtoKinetix is shipping AAGP® to EyeCRO to commence testing Dry Eye Disease […]